Signaturefd LLC Purchases 1,005 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Signaturefd LLC grew its position in Option Care Health, Inc. (NASDAQ:OPCH) by 487.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,211 shares of the company’s stock after buying an additional 1,005 shares during the period. Signaturefd LLC’s holdings in Option Care Health were worth $28,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of OPCH. Graypoint LLC acquired a new stake in Option Care Health during the fourth quarter worth $1,161,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Option Care Health by 6.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,510,131 shares of the company’s stock worth $58,235,000 after acquiring an additional 147,054 shares during the period. Global Alpha Capital Management Ltd. boosted its position in shares of Option Care Health by 38.1% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 68,810 shares of the company’s stock valued at $1,596,000 after acquiring an additional 18,992 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Option Care Health in the fourth quarter valued at about $327,000. Finally, Barclays PLC raised its position in Option Care Health by 180.1% in the third quarter. Barclays PLC now owns 310,194 shares of the company’s stock worth $9,708,000 after purchasing an additional 199,454 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

Insider Activity

In related news, insider Michael Bavaro sold 30,996 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the transaction, the insider now owns 44,974 shares in the company, valued at $1,495,835.24. This represents a 40.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.64% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on OPCH shares. Barrington Research lifted their price objective on Option Care Health from $33.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. Jefferies Financial Group raised Option Care Health from a “hold” rating to a “buy” rating and boosted their price target for the company from $26.00 to $35.00 in a research note on Thursday, January 23rd. JMP Securities reiterated a “market outperform” rating and set a $30.00 price objective (down from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. JPMorgan Chase & Co. lifted their price objective on Option Care Health from $40.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. Finally, Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and upped their target price for the stock from $26.00 to $33.00 in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $33.00.

Option Care Health Trading Up 1.4 %

Shares of OPCH opened at $35.18 on Wednesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73. The company has a market cap of $5.78 billion, a price-to-earnings ratio of 29.56, a PEG ratio of 2.30 and a beta of 1.33. The stock has a fifty day moving average price of $32.11 and a two-hundred day moving average price of $28.33. Option Care Health, Inc. has a 52-week low of $21.39 and a 52-week high of $35.44.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.